Outcomes	O

The	O
primary	O
outcome	O
of	O
the	O
study	O
was	O
a	O
composite	O
measure	O
of	O
progress	B-PrimaryOutcome
to	I-PrimaryOutcome
severe	I-PrimaryOutcome
disease	I-PrimaryOutcome
(	I-PrimaryOutcome
PaO2	I-PrimaryOutcome
/	I-PrimaryOutcome
FiO2	I-PrimaryOutcome
ratio	I-PrimaryOutcome
<	I-PrimaryOutcome
100	I-PrimaryOutcome
)	I-PrimaryOutcome
any	B-TimeFrame
time	I-TimeFrame
within	I-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
of	I-TimeFrame
enrolment	I-TimeFrame
or	O
all	B-PrimaryOutcome
-	I-PrimaryOutcome
cause	I-PrimaryOutcome
mortality	I-PrimaryOutcome
at	B-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
.	O

Primary	O
outcome	O
was	O
considered	O
as	O
“	O
good	O
”	O
if	O
the	O
progress	O
to	O
severe	O
disease	O
or	O
all	O
-	O
cause	O
mortality	O
could	O
be	O
prevented	O
in	O
the	O
28	O
days	O
post	O
enrolment	O
and	O
“	O
poor	O
”	O
if	O
not	O
.	O

The	O
secondary	O
outcomes	O
were	O
clinical	B-SecondaryOutcome
improvement	I-SecondaryOutcome
and	I-SecondaryOutcome
symptom	I-SecondaryOutcome
resolution	I-SecondaryOutcome
on	B-TimeFrame
day	I-TimeFrame
7	I-TimeFrame
;	O
variation	B-SecondaryOutcome
in	I-SecondaryOutcome
fraction	I-SecondaryOutcome
of	I-SecondaryOutcome
inspired	I-SecondaryOutcome
oxygen	I-SecondaryOutcome
(	I-SecondaryOutcome
Fio2	I-SecondaryOutcome
%	I-SecondaryOutcome
)	I-SecondaryOutcome
on	B-TimeFrame
days	I-TimeFrame
1	I-TimeFrame
,	I-TimeFrame
3	I-TimeFrame
,	I-TimeFrame
5	I-TimeFrame
,	I-TimeFrame
7	I-TimeFrame
and	I-TimeFrame
14	I-TimeFrame
;	O
total	B-SecondaryOutcome
duration	I-SecondaryOutcome
of	I-SecondaryOutcome
respiratory	I-SecondaryOutcome
support	I-SecondaryOutcome
during	I-SecondaryOutcome
hospitalization	I-SecondaryOutcome
and	I-SecondaryOutcome
post	I-SecondaryOutcome
enrolment	I-SecondaryOutcome
duration	I-SecondaryOutcome
of	I-SecondaryOutcome
respiratory	I-SecondaryOutcome
support	I-SecondaryOutcome
till	B-TimeFrame
day	I-TimeFrame
28	I-TimeFrame
or	I-TimeFrame
discharge	I-TimeFrame
whichever	I-TimeFrame
is	I-TimeFrame
earlier	I-TimeFrame
;	O
negative	B-SecondaryOutcome
conversion	I-SecondaryOutcome
of	I-SecondaryOutcome
SARS	I-SecondaryOutcome
-	I-SecondaryOutcome
CoV	I-SecondaryOutcome
-	I-SecondaryOutcome
2	I-SecondaryOutcome
viral	I-SecondaryOutcome
RNA	I-SecondaryOutcome
on	B-TimeFrame
days	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
;	O
levels	B-SecondaryOutcome
of	I-SecondaryOutcome
biomarkers	I-SecondaryOutcome
on	B-TimeFrame
days	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
post	I-TimeFrame
enrolment	I-TimeFrame
compared	I-TimeFrame
to	I-TimeFrame
baseline	I-TimeFrame
;	O
requirement	B-SecondaryOutcome
of	I-SecondaryOutcome
vasopressor	I-SecondaryOutcome
support	I-SecondaryOutcome
;	O
and	O
clinical	B-SecondaryOutcome
improvement	I-SecondaryOutcome
on	I-SecondaryOutcome
WHO	I-SecondaryOutcome
ordinal	I-SecondaryOutcome
scale	I-SecondaryOutcome
on	B-TimeFrame
day	I-TimeFrame
0	I-TimeFrame
,	I-TimeFrame
1	I-TimeFrame
,	I-TimeFrame
3	I-TimeFrame
,	I-TimeFrame
5	I-TimeFrame
,	I-TimeFrame
7	I-TimeFrame
,	I-TimeFrame
14	I-TimeFrame
and	I-TimeFrame
28	I-TimeFrame
days	I-TimeFrame
.	O

22	O
The	O
WHO	O
ordinal	O
scale	O
was	O
not	O
mentioned	O
in	O
the	O
initial	O
study	O
protocol	O
but	O
was	O
added	O
midway	O
through	O
the	O
trial	O
as	O
it	O
was	O
felt	O
that	O
it	O
will	O
be	O
a	O
key	O
endpoint	O
in	O
any	O
future	O
meta	O
-	O
analysis	O
.	O

Safety	O
outcomes	O
were	O
frequency	B-OtherOutcome
of	I-OtherOutcome
minor	I-OtherOutcome
and	I-OtherOutcome
serious	I-OtherOutcome
adverse	I-OtherOutcome
event	I-OtherOutcome
(	I-OtherOutcome
death	I-OtherOutcome
and	I-OtherOutcome
invasive	I-OtherOutcome
mechanical	I-OtherOutcome
ventilation	I-OtherOutcome
,	I-OtherOutcome
hemodynamic	I-OtherOutcome
instability	I-OtherOutcome
)	I-OtherOutcome
within	B-TimeFrame
6	I-TimeFrame
hours	I-TimeFrame
of	I-TimeFrame
CP	I-TimeFrame
transfusion	I-TimeFrame
.	O

Relatedness	O
of	O
a	O
serious	B-OtherOutcome
adverse	I-OtherOutcome
event	I-OtherOutcome
with	O
the	O
trial	O
was	O
assessed	O
as	O
per	O
the	O
definitions	O
given	O
by	O
Edwards	O
and	O

Aronson	O
.	O

